1. Medtech Insight

Oncimmune Kicks Off 2018 With China Pact For Lung Cancer Test

 
• By Tina Tan

Oncimmune's commercialization of its early cancer diagnostic technology continues to gather pace as the firm enlists yet another distribution partner in Asia. The exclusive deal is for China, where the market opportunity for the company's EarlyCDT-Lung test is sizeable. The agreement also includes an equity investment by the Chinese partner in Oncimmune.

MT1801_Lung Cancer_47781766_1200

Oncimmune Ltd. has scored its eighth Asian partner – this time, for the enormous Chinese market – to commercialize its EarlyCDT autoantibody-based cancer test platform. The deal will bring in royalty payments for Oncimmune from sales of the tests in China and a new shareholder as its new partner has agreed to make an equity investment in Nottingham, UK-based Oncimmune.

The company announced on Jan. 2 that it has signed a framework agreement with Genostics Company Limited, part of Gene Group Holdings, a Chinese company focused on immunological and molecular diagnostic products in the fields of oncology, pathology, hematology and cytogenetics

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Oncology

More from Device Area

‘Pathologists Are Hungry For AI-Enabled Digital Pathology’

 
• By Natasha Barrow

Digital pathology makes it possible to unlock insights previously hidden to the human eye, “reshaping how we diagnose and treat patients,” said Nathan Buchbinder, co-founder and chief strategy officer at Proscia. He shared his views on the future of digital pathology and the lessons he has learned from working with pathologists.

First At-Home Cervical Cancer Screening Tool Gets FDA Clearance

 
• By Elizabeth Orr

The US FDA has approved the Teal Wand, the first at-home cervical cancer screening device. Capable of detecting preclinical cancer with 96% accuracy, it will launch in California in June and expand nationwide soon after.

SS Innovations Files For De Novo For SSi Mantra 3 Surgical Robotic System For Multispecialty Indications

 
• By Marion Webb

SS Innovations announced plans to file a de novo application with the US FDA for its SSi Mantra 3 surgical robot, already approved for marketing in six countries. The Florida-based firm also plans to pursue the CE mark for European commercialization.